ArticleBMC infectious diseases2026
In-silico design of a multi-epitope vaccine candidate against Strongyloides stercoralis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStrongyloides stercoralis is a soil-transmitted helminth causing strongyloidiasis, mainly affecting impoverished populations in tropical and subtropical regions. Despite its high global prevalence, affecting an estimated 613.9 million people, it remains neglected in public health initiatives. Current treatments, including albendazole and ivermectin, show variable efficacy and face potential resistance, making vaccine development critical for long-term control and achieving WHO targets.
methodsWe employed an immunoinformatics approach to design a multi-epitope vaccine candidate by combining B-cell and T-cell epitopes from key L3-stage proteins involved in S. stercoralis infection. In addition, interactions with TLR4 were implemented to assess the vaccine’s ability to elicit an innate immune response.
resultsThe selected proteins exhibited strong conservation, suggesting potential cross-protection across Strongyloides strains. The vaccine candidate was predicted to be antigenic, non-allergenic, and immunogenic, with immune simulation demonstrating robust activation of humoral and cellular immune responses. Extensive HLA coverage analysis indicated broad population applicability. Additionally, protein–protein docking and normal-mode analyses indicated efficient binding and stable interaction of the vaccine candidate with TLR4.
conclusionThis study provides a promising approach to designing multi-epitope vaccines against S. stercoralis designed through integrative immunoinformatics. Overall, the designed vaccine candidate demonstrated immunogenicity and safety features that warrant further experimental validation in vitro and in vivo. These findings lay important groundwork for future vaccine development aimed at improving the prevention and control of strongyloidiasis globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.